Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C

Expert Opinion on Drug Safety

Volumn 14, Issue 3, 2015, Pages 473-484

  D'Ambrosio, Roberta ^a   Aghemo, Alessio ^a   Colombo, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Hepatitis C virus; Ledipasvir; PegInterferon; Ribavirin; Sofosbuvir

Indexed keywords

LEDIPASVIR PLUS SOFOSBUVIR; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; URIDINE PHOSPHATE;

ANEMIA; ARTICLE; CHILL; CLINICAL TRIAL (TOPIC); DECOMPENSATED LIVER CIRRHOSIS; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FATIGUE; FEVER; HEADACHE; HEPATITIS C; HUMAN; INFECTION; INSOMNIA; KIDNEY DISEASE; LIVER TRANSPLANTATION; NAUSEA; POSTMARKETING SURVEILLANCE; RASH; VIRUS RESISTANCE; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; DRUG COMBINATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE;

EID: 84923360985     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1009035     Document Type: Article

References (50)

1. Lee MH, Yang HI, Lu SN, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012;206:469-77
2. McCombs J, Matsuda T, Tonnu-Mihara I, et al. The risk of longterm morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a department of veterans affairs clinical registry. JAMA Intern Med 2014;174:204-12
3. European Association for the Study of the Liver. Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011;55:245-64
4. Aronsohn A, Reau N, Jensen D. Preparing for the uncertain yet inevitable: off-label combinations of antiviral agents in hepatitis C virus. Hepatology 2014;59:1688-91
5. Hézode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicenter cohort of the French Early Access Programme (ANRS CO20 -CUPIC). J Hepatol 2013;59:434-41
6. Foster GR, Zeuzem S, Andreone P, et al. Sustained virological response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure. J Hepatol 2013;58:488-94
7. Vierling JM, Zeuzem S, Poordad F, et al. Safety and efficacy of boceprevir/ peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials. J Hepatol 2014;61:200-9
8. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol 2014.61:373-95; Available from: http:// files.easl.eu/easl-recommendations-ontreatment of-hepatitis-C/index.html [Last accessed 29 September 2014]
9. Martel-Lafferriere V, Dietrich DT. GS 7977: a promising nucleotide analog NS5B polymerase inhibitor of HCV. Future Virol 2012;7:537-46
10. Kirby B, Gordi T, Symonds WT, et al. Population pharmacokinetics of Sofosbuvir and its major metabolite (GS-331007) in healthy and HCVinfected subjects. 64th annual meeting of the american association for the study of liver diseases; 1-5 November 2013; Washington DC
11. Degasperi E, Aghemo A. Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives. Hepat Med 2014;6:25-33
12. Liu XI, Wang Y, Zhang G, et al. Efficacy and safety of sofosbuvir-based therapy for the treatment of chronic hepatitis C in treatment-naïve and treatment-experienced patients. Int J Antimicrob Agents 2014;44:145-51
13. Rose L, Bias TE, Mathias CB, et al. Sofosbuvir: a nucleotide NS5B inhibitor for the treatment of chronic hepatitis C infection. Ann Pharmacoter 2014;48:1019-29
14. Flamm SL, Everson GT, Charlton M, et al. Ledipasvir/Sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study. Hepatology 2014;60:91A
15. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013;368:34-44
16. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87
17. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013;368:1867-77
18. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV Genotypes 2 and 3. The VALENCE trial. N Engl J Med 2014;370:1993-2001
19. Afdhal N, Everson G, Calleja JL, et al. Sofosbuvir and ribavirin for the treatment of chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virological response and safety. J Hepatol 2014;60:S28
20. Curry MP, Forns X, Chung RT, et al. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation. Hepatology 2013;58(Suppl 1):314A
21. Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa 2a and ribavirin for treatment naïve patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomized, multicenter phase 2 trial. Lancet 2013;381:2100-7
22. Tran TT, Morgan TR, Thuluvath PJ, et al. Safety and efficacy of treatment with sofosbuvir+GS-5816ribavirin for 8 or 12 weeks in treatment naive patients with genotype 1-6 HCV infection. Hepatology 2014;60:58A
23. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an openlabel, randomised, phase 2 trial. Lancet 2014;383:515-23
24. Gane EJ, Stedman CA, Hyland RH, et al. Efficacy of nucleotide polymerase inhibitor Sofosbuvir plus the NS5A inhibitor Ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 2014;146:736-43
25. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-98
26. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-88
27. Bourlière M, Sulkowski M, Omata M, et al. An integrated safety and efficacy analysis of >500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without ribavirin. Hepatology 2014;60:239A
28. Gane E, Hyland RH, An D, et al. Sofosbuvir/ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients, decompensated genotype-1 patients, and genotype-1 patients with prior sofosbuvir treatment experience. J Hepatol 2014;60:S3
29. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomized study. Lancet 2014;384(9956):1756-65
30. Sulkowski M, Vargas H, Di Bisceglie A, et al. Safety and Efficacy of Sofosbuvir (SOF) in Combination with Simeprevir (SIM) + ribavirin (RBV) in Patients with Genotype 1: interim Results of a Prospective, Observational Study. Hepatology 2014;60:660A
31. Morelli G, et al. Open-label study to evaluate safety, tolerability, and efficacy of telaprevir in combination with sofosbuvir in treatment-naïve patients with genotype 1 hepatitis c virus infection [poster 63169]. AASLD/EASL Special Conference; 12-13 September 2014; New York
32. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus Sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211-21
33. Pellicelli AM, Montalbano M, Lionetti R, et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Dig Liver Dis 2014;46:923-7
34. Sovaldi® label (Sofosbuvir). Package Insert. 2014
35. Forns X, Garcia-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003;39:389-96
36. Carrion JA, Martinez-Bauer E, Crespo G, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009;50:719-28
37. Aghemo A, Donato MF. Sofosbuvir treatment in the pre and post liver transplantation phase: the sooner, the better. Gastroenterology 2015;148:13-16
38. Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002;35:680-7
39. Blasco A, Forns X, Carrion JA, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006;43:492-9
40. Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis. J Hepatol 2004;41:830-6
41. Mathias A, Cornpropst M, Clemons D, et al. No clinically significant pharmacokinetic drug-drug interactions between sofosbuvir (GS-7977) and the immunosuppressant cyclosporine A or tacrolymus in healthy volunteers. 64th Annual Meeting of the American Association for the Study of Liver Diseases; 1-5 November 2013; Washington, DC
42. Forns X, Prieto M, Charlton M, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C including fibrosing cholestatic hepatitis following liver transplantation. J Hepatol 2014;60:S26
43. Degasperi E, Aghemo A. Clinical drivers in naïve patient eligibility for treatment of chronic hepatitis C. J Viral Hepat 2012;19(Suppl 1):3-6
44. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17
45. Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206
46. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16
47. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-68
48. Colombo M, Strasser S, Moreno C, et al. Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C: the international telaprevir access program. J Hepatol 2014;61:976-83
49. Afdhal N, Reddy R, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-93
50. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided Telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365:1014-24